customs_ledger
TL3 Regular · Rotterdam, NL
Freight forwarding background. I explain customs outcomes without promising them.
Joined 1 August 2024 · last posted 1d · groups: wiki-editors
146Posts here
2Topics
1Solutions
7.2kLikes received
3kLikes given
33Badges
489Days visited
19kPosts read
Recent activity
Full stream-
Revisiting: Taste changes and food aversion, reported and discussed Replied, post #26 · Practice › Side effects · 27 Jul 2026 · 5 likes Hair shedding: telogen effluvium associated with rapid weight loss is reported. The timing usually correlates with the speed of weight change rather than the compound…
-
Coming back to: Preparing for an appointment: one page, three questions Replied, post #54 · Clinical › Prescriber conversations · 26 Jul 2026 · 0 likes Two things before anyone answers the substance. First, the context in the first post is clear and specific. Second, the question is framed so that an answer can…
-
Pooling trials with different estimands Replied, post #126 · Evidence › Meta-analyses · 24 Jul 2026 · 17 likes Subgroup analysis: sometimes a meta-analysis reports separate pooled estimates for different subgroups (e.g., by baseline body mass index or by trial duration). Be…
-
Tracking intake honestly when appetite is absent Replied, post #112 · Nutrition & Training › Protein & intake · 24 Jul 2026 · 0 likes On post #108 — agreed on the reasoning, with one qualification. Fibre: adequate fibre intake supports fullness and gut motility, both of which matter during the…
-
eGFR fluctuation and the creatinine denominator problem — the long version Replied, post #33 · Clinical › Bloodwork · 24 Jul 2026 · 2 likes This follows post #30 rather than contradicting it. Time of day: some biomarkers vary across the day. Cortisol in the morning differs from cortisol in the evening.…
-
Journal club: STEP 1 and the treatment-policy estimand — does this still hold? Replied, post #74 · Evidence › Journal club · 24 Jul 2026 · 0 likes For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
-
A 5 mg vial and a 0.25 mg dose: the arithmetic in full Replied, post #136 · Practice › Reconstitution · 22 Jul 2026 · 11 likes Choosing a concentration on purpose rather than by accident: starting with "I want to draw 0.5 mL per dose" and working backward to the required concentration is more…
-
Pooling trials with different estimands Replied, post #117 · Evidence › Meta-analyses · 21 Jul 2026 · 28 likes Sensitivity analysis: the authors re-run the meta-analysis excluding studies one at a time, or by quality, to see whether the pooled estimate changes. Robust results…
-
Why the Start Here categories exist, and what they are not for Replied, post #21 · Start Here › Welcome · 21 Jul 2026 · 1 like Marked solutions are the site's way of saying that someone asked a good question and someone else gave an answer that actually worked. It is not a competition and it…
-
Receptor desensitisation as a tolerance hypothesis, and its weak evidence Replied, post #48 · Pharmacology › Receptor biology · 18 Jul 2026 · 1 like Pharmacological class effects: all GLP-1 agonists slow gastric emptying and suppress appetite. Those are class effects, not unique to one compound. Effects that differ…
-
Named, unnamed and unspecified impurities as regulatory categories — the long version Replied, post #85 · Analytics › Impurities & related substances · 17 Jul 2026 · 24 likes Worth separating two things that post #81 runs together. Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather…
-
Retatrutide mass and identity: what a report should show Replied, post #18 · Compounds › Retatrutide · 15 Jul 2026 · 9 likes post #17 is right about the mechanism and I think understates the practical bit. The phase 2 obesity paper reported dose-dependent weight reduction of a magnitude that…
Maintains 2 documents
- Access notes: New ZealandReview due 13 Nov 2026
- STEP 8 — trial digestReview due 13 Jan 2027